The Structural Basis of PI3K Cancer Mutations: From Mechanism to Therapy

Shujuan Liu, Stefan Knapp, and Ahmed Ashour Ahmed

Abstract

While genetic alteration in the p85α-p110α (PI3K) complex represents one of the most frequent driver mutations in cancer, the wild-type complex is also required for driving cancer progression through mutations in related pathways. Understanding the mechanistic basis of the function of the phosphoinositide 3-kinase (PI3K) is essential for designing optimal therapeutic targeting strategies. Recent structural data of the p85α/p110α complex unraveled key insights into the molecular mechanisms of the activation of the complex and provided plausible explanations for the well-established biochemical data on p85/p110 dimer regulation. A wealth of biochemical and biologic information supported by recent genetic findings provides a strong basis for additional p110-independent function of p85α in the regulation of cell survival. In this article, we review the structural, biochemical, and biologic mechanisms through which p85α regulates the cancer cell life cycle with an emphasis on the recently discovered genetic alterations in cancer. As cancer progression is dependent on multiple biologic processes, targeting key drivers such as the PI3K may be required for efficacious therapy of heterogeneous tumors typically present in patients with late-stage disease. Cancer Res; 74(3); 641–6. ©2014 AACR.

Introduction

The recent progress in our understanding of the genetic basis of cancer has made it clear that there is significant intratumor heterogeneity at the single nucleotide level. Single-cell whole-exome data from model tumors revealed previously unrecognized diversity of coding mutations. Such profound heterogeneity poses a challenge for designing successful targeted therapies for patients with cancer and calls for novel strategies to circumvent this problem. One plausible approach is to target biologic processes that are required for cancer progression. Such processes may be driven by mutations in key drivers but modulated and eventually implemented by a panel of proteins that directly contribute to an individual biologic process. Here, we review the mechanistic basis of the p110α (PIK3CA)/p85α (PIK3R1) phosphoinositide 3-kinase (PI3K) function, a key modulator of several biologic processes such as survival, proliferation, migration, invasion, and metastasis and, therefore, an attractive target for therapy.

In 1985, Whitman and colleagues showed that the transforming ability of the polyoma virus middle T antigen (PyMT), a membrane-bound tyrosine kinase, closely correlated with phosphatidylinositol (PI) kinase activity (1). This kinase activity was later found to phosphorylate the 3' position on 4,5-diphosphorylated inositol phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) to yield PtdIns(3,4,5)P3 (2). The generation of PtdIns(3,4,5)P3 results in activation of many intracellular signaling pathways, including metabolism, proliferation, survival, motility, and morphology. Although PyMT was later found to have independent oncogenic properties, its regulation of PI3K revealed that hyperactivation of this pathway can lead to uncontrolled proliferation, enhanced migration, and adhesion-independent growth. Recent observations revealed further important insights into the mechanism of regulation and activation of the PI3K pathway in cancer.

PI3K activation occurs at the cell membrane

The p110α (PIK3CA)/p85α (PIK3R1) dimer receives regulatory stimuli from transmembrane receptors via tyrosine kinases. The protein tyrosine kinases involved can be the receptor itself, such as growth factor receptors [e.g., platelet-derived growth factor receptor (PDGFR), EGFR receptor (EGFR), and insulin-like growth factor receptor (IGFR)] or kinases that are activated by direct or indirect association with the receptor (e.g., Src family of protein tyrosine kinases; Fyn and Lck). These tyrosine kinases are able to phosphorylate critical tyrosine residues within activation motifs, often located within the receptors themselves (e.g., auto-phosphorylation of the YXXM motif in PDGFR) or are present on protein adaptors (e.g., IRS, Shc, Grb, Gab, and Cbl). As a multidomain-containing protein, the regulatory subunits of PI3K (p85α, p55, p50) bind to the phosphorylated pYXXM motif via their
SH2 domains (Fig. 1A) resulting in PI3K membrane recruitment and generation of the second messenger PI (3,4,5) P3. In addition, the RBD domain of p110α catalytic subunit (Fig. 1A) is recruited to the plasma membrane through direct binding to the GTP-bound active form of membrane-bound (myristylated) Ras.

PI3K initiates the intracellular signaling cascades by generating phospholipids. The production of second messenger phosphatidylinositol-3, 4, 5-trisphosphate (PtdIns(3,4,5)P3) leads to activation of a series of signaling pathways. The cellular level of PtdIns(3,4,5)P3 is tightly regulated by the opposing activity of PI3K and PtdIns(3,4,5)P3 phosphatases (PTEN, SHIP1, and SHIP2). PTEN is an important tumor suppressor, which functions as a lipid phosphatase that removes a phosphate group from position 3 of PtdIns (3,4,5)P3 and converts it back to PI (4,5) P2. PtdIns(3,4,5)P3 can also be dephosphorylated at position 5 by SHIP1 or SHIP2 to form PI (3,4) P2. PtdIns(3,4,5)P3 provides docking sites for signaling molecules with pleckstrin-homology (PH) domains and recruits them to cellular membranes (3). The most important effector of PI3K signaling is the PH domain–containing serine/threonine kinase AKT and its activator PDK1 (3-phosphoinositide-dependent kinase 1). AKT is translocated to the plasma membrane by association with...
PI3K mutations in cancer cluster at activating hotspots

In 2004, Samuels and colleagues first reported the analysis of 8 PI3K and 8 PI3K-like genes in 35 colorectal cancers, PIK3CA was the only gene that showed somatic mutations. More than 75% of all sequence alternations clustered at the helical and the kinase domains (Fig. 1B). Ectopically expressed hotspot mutant H1047R was found to have higher lipid kinase activity than the wild-type kinase (4). Subsequent analysis of all coding exons of PIK3CA identified mutations in 74 of 234 colorectal cancers (32%), 4 of 15 glioblastomas (27%), 3 of 12 gastric cancers (25%), 1 of 12 breast cancers (8%), and 1 of 24 lung cancers (4). Hotspot mutations (E542K, E545K, and H1047R) were subsequently reported to stimulate kinase activity and to exert strong oncogenic drive (5). In 224 tumor and normal pairs of colorectal cancers in The Cancer Genome Atlas (TCGA) genome scale analysis, the PIK3CA was one of the 8 most frequently mutated genes (18% frequency of mutations) in the nonhypermutated tumor subgroup. There are also reports showing mutations of PIK3CA in 52.4% of 42 endometrioid endometrial cancers (EEC), 33.3% of 66 nonendometrioid endometrial cancers (NEEC; ref. 6).

In addition, mutations in the PI3K regulatory subunits have been described. PIK3R1, PIK3R2, and PIK3R3 encode p85α (which through alternative transection initiation sites encode 2 shorter isoforms p55α and p50α), p85β, and p55γ regulatory subunits, respectively. PIK3R1 was mutated in 9 of 10 colorectal (8%), 1 of 2 breast (2%), and 1 of 6 pancreatic (17%) tumor samples (7). In a TCGA cohort, 9 PIK3R1 somatic mutations were found in the 91 sequenced glioblastomas and 8 of 9 detected PIK3R1 somatic mutations clustered at the ish2 domain (Fig. 1A–D; ref. 8). A recent study of 42 EECs and 66 NEECs revealed an unusually high frequency of PIK3R1 mutations. PIK3R1 was somatically mutated in 43% of EECs and 12% of NEECs. The majority of mutations (93.3%) were localized at the p85α nSH2 and ISH2 domains (9). Therefore, many mutations would also affect the shorter isoforms p55α and p50α if those were expressed. In the recent TCGA analysis of 510 human breast tumors, 14 PIK3R1 mutations were detected, and most of the mutations clustered in the ISH2 domain (particularly at amino acids 456–469 and 564–575; ref. 10). Mutations in PIK3R2 or PIK3R3 are rare (8).

How p85 modulates the catalytic activity of p110

A wide variety of PI3K-activating cancer mutations occur at the interface between P110α and p85α (Fig. 1B), suggesting that this interaction plays a key role in regulating the complex. In the absence of p85α, monomeric p110α is rapidly degraded (11), whereas coexpression of p85α stabilizes a low-activity state of p110α (12). Strikingly, the isolated ISH2 domain that binds to a large surface spanning the ABd domain and a groove formed by the helical, catalytic, and C2 domain of p110α does not inhibit the p110α kinase. In contrast, inhibition of p110α by p85α requires the presence of the nSH2 domain. However, the nSH2 domain was not well-defined in the p110α/p85α crystal structures and the interaction could only be modeled on the basis of biochemical data. In the H1047R-mutant p110α/p85α structure, the nSH2 domain acts as a central scaffold binding to the interface formed by the kinase, helical, and C2 domains (Fig. 1B). Biochemical data showed that phosphotyrosine peptides are capable of activating the nSH2/p110 complex but not the ISH2/p110 complex in vitro through their interaction with the nSH2 domain (Fig. 1C). This suggests that the nSH2 domain is required for the inhibition of the p110 kinase and that modulation of its conformation may have a strong effect on modulating the p110 kinase activity (13–16). It is, therefore, thought that the main function of the ISH2 domain is to act as a tether for p110, holding the p85/p110 subunits together, and that this interaction enables a second regulatory contact between the nSH2 and p110α that inhibits the p110 activity by inducing conformational change.

Published OnlineFirst January 23, 2014; DOI: 10.1158/0008-5472.CAN-13-2319
associated regulatory subunit. After stimulation by receptor tyrosine kinases, the nSH2 domain moves away from the p110α helical domain to accommodate the binding of tyrosine-phosphorylated activators (e.g., PDGFR or IRS1). This allosteric regulatory mechanism brings p110α near its lipid substrates in the membrane and releases the inhibitory effect of p85α on p110α. Importantly, the p110 helical domain loop that contains sites of hotspot mutations (e.g., E542K and E545K) is located at the site where phosphotyrosine peptides bind to the nSH2 domain and potentially produce an electrostatic clash with lysine 379 of the nSH2 domain (Fig. 1C). It is thought that the mutant p110 lysine residues occupy the space that, under physiologic conditions, would only be occupied by phosphotyrosine partners and would therefore result in constitutive relief of inhibitory binding between nSH2 and p110 (Fig. 1C). Interestingly, K379E nSH2 mutants inhibit the p110α-E545K oncogenic mutant whereas the wild-type p85 nSH2 does not, suggesting that the charge reversal reestablished the critical inhibitory interaction (14).

The structure of the common H1047R mutant in complex with p85α revealed some critical differences when compared with the structure of the wild type. In contrast to the wild-type histidine residue, the arginine residue does not interact with the activation loop leucine 596 but orients its side chain away from the catalytic domain facilitating membrane recruitment. The mutant structures are also in a region close to the C-terminus of p110α (residues 1,050–1,062) and induce structural changes in the loop spanning residues 564–574, both regions known to be important for the recruitment of the kinase complex to the plasma membrane. These structural changes may explain the observation that H1047R does not require binding to activated RAS, which synergizes with the recruitment of the wild-type kinase complex to the cell membrane (19). This explanation is consistent with the finding that H1047R mutants retain their transforming ability even if their interaction with RAS is abolished by mutating the RBD domain (20). Interestingly, both E542K and E545K mutants appear to require RAS binding to retain their transforming ability, suggesting that the helical domain and kinase domain mutants activate the kinase through independent mechanisms (20).

The majority of hotspot mutants of p85α are clustered at the nSH2-ISH2 domains, and many have been shown to induce a gain of P3K enzymatic function, oncogenic cellular transformation, and cellular proliferation and to enhance P3K signaling (21). The structure of the p85/p110 complex suggests that these PIK3R1 point mutations and insertions/deletions may disrupt the inhibitory effect of p85α on p110α.

Residues D560 and N564 of p85α are highly mutated in tumors. The structural data predict that the effect of mutating these residues would be similar to mutating N345 of the C2 domain of p110α (22). N345K is within hydrogen-bonding distance from D560 and N564 of nSH2 of p85α, and mutations at these residues may disrupt the inhibitory interaction of the C2 domain with ISH2 (13). Consistent with this model, deletion of p85α after residue 571 (p85αni-572stop), or mutations of residues D560K/N564K, leads to constitutive P3K activation (23). Analysis of the D560Y, N564D, D560Y/N564D, and DVQL579 mutants revealed that they retain the ability to bind to p110α, p110β, and p110δ but that they have less inhibitor effect on the kinases leading to enhanced cell survival, AKT activation, anchorage-independent cell growth, and oncogenesis (7).

An analysis of the oncogenic activity of 9 mutants of p85α found in glioblastoma (24) and one engineered mutation (K379E (14)) was conducted, and a comparison was made with the p110α mutant H1047R. When overexpressed in chicken embryo fibroblasts (CEF), all mutants induced oncogenic cellular transformation, increased proliferation, and enhanced downstream signaling. Among them, the most potent mutants, K549delN and DKRMN5560delN, showed specific transforming activity similar to the highly oncogenic p110α mutant H1047R. These 2 residues are located on equivalent positions of 2 alternate helices in the iSH2 domain and are also in close proximity to the C2 domain of p110α. Mutations at these residues may disrupt the α-helical structure of the iSH2 domain and consequently may disrupt interactions with the C2 domain. In addition, the 3 C-terminal iSH2 mutants (R574fs, T576del, and W583del) all occur in the long α helix of the iSH2 domain and may, therefore, contribute to the abnormal interface between the iSH2 and the C2 domains (21).

The GAP domain (Fig. 1A) of p85α has been shown to harbor activating mutations in endometrial and other cancers (7, 9, 25). The mechanistic basis by which these mutations activate the PI3K pathway appears to be through modulating the interaction between p85α and PTEN or other p85α interaction partners rather than through a direct effect on p110α.

**P110α-independent regulation of cell survival by p85α**

The BH domain (also called GAP domain, Fig. 1A) of p85α bears a conserved sequence homology to a large group of Rho GTPase-activating proteins (RhoGAP). RhoGAPs catalyze the hydrolysis of GTP that is bound to small GTPases (Rho, Rac, and CDC42), leading to their inactivation. In vitro studies showed that the p85α regulatory subunit can interact with the GTP-bound forms of the CDC42 and Rac1. Ectopic expression of the BH domain containing forms of p85α (e.g., p85αt), but not the BH-deficient form p50, was found to decrease actin stress fibers and reduce focal adhesion complexes, resembling the CDC42-dependent cytoskeletal changes induced by PDGF (26). In addition, p85 can simultaneously bind to CDC42 and Septin2 via the BH domain and a region around nSH2/ISH2, respectively. This subsequently regulates CDC42 activity in cytokinesis and its localization at the cleavage furrow. Thus, p85 contributes to the cell division during the later phases of the cell cycle (27). P85α was found to possess GAP activity for RAB5 and RAB4 proteins that localizes on early endosomes and regulates vesicular fusion events (28). Because of the co-localization between p85 that is bound to PDGFR during receptor tyrosine kinase endocytosis and the early endosomal proteins RAB4 and RAB5, it is thought that p85 regulates the GTP-bound state of RAB4 and RAB5 (28). Thus, at least in some model systems, the BH domain may possess GAP activity. In addition, the SH2 domains of p85α were found to interact with phosphorylated and activated STAT5 in leukemia cells, and this resulted in activation of the P3K pathway (29). Whether this interaction also modulates the transcriptional activity of STAT5 remains unknown.
In cells, the p85α subunit is about 30% more abundant than p110α. A model describing the balance between the 2 subunits of PI3K suggests that the extra 30% of p85 exists as a free monomer that is unable to transmit a signal but competes for binding to the phosphorylated insulin receptor substrate (IRS) proteins to inhibit signaling via the p85/p110 dimer. Heterozygous disruption of PIK3R1 will only affect the monomer p85, but with little effect on the p85/p110 dimer, which results in increased AKT activity and decreased apoptosis by IGF-1 through upregulated PtdIns(3,4,5)P3 production. In contrast, complete depletion of p85 results in a significant increase in apoptosis due to reduced PI3K-dependent signaling (30).

Concluding Remarks and Future Directions

The PI3K is a good example of how studying human disease can significantly enhance the understanding of fundamental protein function. The discovery of hotspot mutations in cancer combined with a wealth of biochemical and structural data unraveled significant insights into the mechanistic basis of regulation of p110 catalytic activity. These insights underpinned the efforts to invent new diagnostic and therapeutic tools for targeting this complex in cancer and other diseases. Future research is likely to focus on two directions. At the molecular level, it is crucial that the role of the SH3 and the BH domains of p85α in regulating the activity of the kinase is investigated at the structural level to enable a full understanding of the intrinsic regulation of the PI3K activity. At the translational level, recent genetic discoveries of profound heterogeneity challenged the established dogma of therapeutically targeting of individual genetic alterations. Targeting a vital cancer process to prevent the evolution of the next generation of the cancer progeny is a plausible approach. As the PI3K is a key component of many vital cellular processes, deeper understanding of its role in regulating cancer progression is needed to allow its effective targeting.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

This work was funded by the Medical Research Council, Target Ovarian Cancer, and National Institute of Health Research.

Received August 12, 2013; revised December 4, 2013; accepted December 13, 2013; published OnlineFirst January 23, 2014.


The Structural Basis of PI3K CancerMutations: From Mechanism to Therapy

Shujuan Liu, Stefan Knapp and Ahmed Ashour Ahmed


Updated version Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-13-2319

Cited articles This article cites 30 articles, 19 of which you can access for free at:
http://cancerres.aacrjournals.org/content/74/3/641.full.html#ref-list-1

Citing articles This article has been cited by 2 HighWire-hosted articles. Access the articles at:
/content/74/3/641.full.html#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.